NASDAQ: INCRIntercure Ltd Stock
$3.29+0.14 (+4.44%)
Updated May 17, 2024
INCR Price
$3.29
Fair Value Price
N/A
Market Cap
$149.93M
52 Week Low
$0.99
52 Week High
$3.72
P/E
-9.06x
P/B
1.24x
P/S
0.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$94.81M
Earnings
-$17.07M
Gross Margin
29.6%
Operating Margin
-11.25%
Profit Margin
-17.4%
Debt to Equity
0.72
Operating Cash Flow
-$15M
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
INCR Overview
Intercure Limited produces and distributes medical cannabis products in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed industries. InterCure was incorporated in 1994 and is headquartered in Herzliya, Israel.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INCR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
INCR is good value based on its book value relative to its share price (1.24x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.2x)
P/B vs Industry Valuation
INCR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more INCR due diligence checks available for Premium users.
Be the first to know about important INCR news, forecast changes, insider trades & much more!
INCR News
Valuation
INCR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-9.06x
Industry
-1.01x
Market
30.97x
INCR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.24x
Industry
2.2x
INCR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INCR's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
INCR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INCR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$216.7M
Liabilities
$90.8M
Debt to equity
0.72
INCR's short-term assets ($111.68M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INCR's short-term assets ($111.68M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
INCR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INCR vs Pharmaceutical Stocks
Intercure Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.